Although CYP3A4 and CYP3A5 play a role in imatinib metabolism, there is currently no reliable data confirming that any variation in these genes may predict therapy outcome in CML [4]. This evidence concerns the gene CYP3A4 and chronic myelogenous leukemia, BCR-ABL1 positive.